When direction is hard to read, teams usually respond in one of two ways. Some narrow the lens. They extend today’s paradigm forward and build around a single ‘expected’ future. The strategy feels coherent and manageable. It is also fragile. Variations in sequencing, access, standards of care or prescriber behaviour can rapidly undermine
what once appeared well-founded.

Others widen the lens until commitment becomes difficult. Scenarios multiply. Futures proliferate. Significant energy goes into describing what could happen. Decision-making
slows, because every choice feels open to challenge. Strategy turns cautious, conditional and harder to sustain.

Both patterns share a deeper issue. They drift away from the individuals who ultimately determine what succeeds – prescribers, operating within real constraints and making real trade-offs. Strategy loses traction when the future is treated as an abstract construct rather than a set of decisions made in practice.

The Future Worlds thinking framework introduces discipline by narrowing uncertainty into a small number of contexts teams can act against.

Each ‘world’ reflects a materially distinct way oncology care could plausibly unfold:
how patients are identified; where unmet need persists; how therapies are sequenced;
what ‘good’ looks like to prescribers and which trade-offs they are prepared to make. Working with a limited set of plausible worlds sharpens strategic focus and changes the quality of discussion, anchoring debate in realistic decision contexts rather than abstract futures.

This reframes early strategy. Broad landscape understanding begins to guide practical judgement, helping teams identify where future opportunity is likely to endure, even as the market evolves around the programme. The most valuable output is a series of upfront choices that hold up across conditions leaders cannot control

Earlier clarity emerges around opportunity spaces with genuine staying power: patient segments; lines of therapy and niches that remain relevant as treatment approaches develop over time.

Teams become more deliberate about evidence generation. Data is prioritised for its ability to support decisions across multiple future contexts, not just one anticipated outcome. Proof is built to inform where to concentrate, how to differentiate and what must be true for success.

Portfolio coherence improves. Assets can be considered against the same contexts, reducing internal competition and strengthening investment logic across the pipeline.

Teams also gain confidence to stop. In oncology, optionality often feels prudent. In practice, it delays commitment and diffuses focus. Future Worlds thinking helps teams
make trade-offs with clearer rationale.

Many teams equate waiting with prudence. Oncology rarely affords that luxury. By the time the path ahead becomes easier to interpret, differentiation is harder to establish, budgets are allocated and critical decisions have already been made.

The organisations that succeed do not move faster because they know the future. They move sooner because they plan for change and commit to opportunities that survive it.

In oncology, strategy needs to earn its right to exist under pressure. Future Worlds thinking is one way of fostering that resilience, before choices are constrained by time, cost and evidence already set in motion.